Expanded Access for CC-486

NCT03723135 · clinicaltrials.gov ↗

APPROVED_FOR_MARKETING

Status

INDUSTRY

Sponsor class

Conditions

Acute Myelogenous Leukemia (AML)

Interventions

DRUG: CC-486

Sponsor

Celgene